静脉注射蔗糖铁对血液透析患者FGF23水平及钙磷代谢的影响被引量：4

下载PDF

导出

摘要目的探讨静脉注射蔗糖铁对血液透析患者成纤维细胞生长因子(FGF)23水平及钙磷代谢的影响。方法将2011年1月至2013年12月该院86例行维持性血液透析患者分为实验组和对照组各43例,均行常规血液透析治疗,实验组再给予静脉输注蔗糖铁治疗,为期1个月。于治疗前、治疗1、2个月后随访记录并比较两组患者FGF23、1,25-二羟维生素D3〔(25-(OH)Vit D3〕、甲状旁腺激素(PTH)、钙(Ca)、磷(P)、血红蛋白(Hb)、C反应蛋白(CRP)、血尿素氮(BUN)、血肌酐(SCR)、血清铁蛋白(SF)水平。结果两组治疗前FGF、1,25-(OH)Vit D3、Ca、P及PTH比较差异无统计学意义(P>0.05);治疗1个月后,两组Ca、P水平无显著变化(P>0.05),而实验组FGF23、PTH均有明显的下降,1,25-(OH)Vit D3有明显上升(P<0.05);2个月后随访,两组除Ca、P水平无显著变化(P>0.05),其余各指标水平均有统计学差异(P<0.05)。两组治疗前SF、BUN、SCR、CRP及Hb比较无统计学差异(P>0.05);治疗1个月后,对照组各指标无显著变化(P>0.05),而实验组BUN、SCR、CRP均有明显下降,SF、Hb明显上升(P<0.05);2个月后随访,两组除BUN水平无显著变化(P>0.05),其余各指标比较差异均有统计学意义(P<0.05)。结论血液透析患者在治疗时进行静脉输注蔗糖铁,对患者体内FGF-23水平及钙磷代谢紊乱均有明显的改善效果,可提高患者的生存质量。

作者肖英张红霞冯现竹张晓宁张洪源

机构地区东营市胜利油田中心医院肾内科

出处《中国老年学杂志》 CAS CSCD 北大核心 2015年第14期3995-3997,共3页 Chinese Journal of Gerontology

关键词血液透析蔗糖铁成纤维细胞生长因子23 钙磷代谢

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献13

1Timothy V. Nguyen.Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients[J]. American Journal of Health-System Pharmacy . 2009 (12)
2A 12‐week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia[J]. Acta Obstetricia et Gynecologica Scandinavica . 2010 (9)
3Charytan C,Bernardo MV,Koch T A,et al.Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease:a randomized,active-controlled,multi-center study. Nephrology Dialysis Transplantation . 2013
4Alejandro Martin-Malo,Ana Merino,Julia Carracedo.Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrology Dialysis Transplantation . 2012
5Ryndina N,Kravchun P,Tytova G,et al.Cardiohemodynamic features and character of depressive disorders in patients with anemia varying grades of severity with chronic heart failure and chronic kidney disease. Georgian Med News . 2013
6Adhikary L,Acharya S.Efficacy of i.v.iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy. J Nepal Med Assoc . 2011
7Toblli Jorge E,Cao Gabriel,Olivieri Leda,Angerosa Margarita.Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association . 2010
8Sonnweber Thomas,Theurl Igor,Seifert Markus,Schroll Andrea,Eder Susanne,Mayer Gert,Weiss Günter.Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association . 2010
9Macdougall IC,Strauss WE,Mc Laughlin J,et al.A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol . 2014
10Park J,Chang JW,Lee JS,et al.Efficacy of low-dose i.v.iron therapy in haemodialysis patients. Nephrology . 2009

二级参考文献43

1侯凡凡,任昊,郭志坚,陈平雁,梁敏,张训.单核细胞RAGE表达上调:慢性肾功能衰竭微炎症的机制[J].中华医学杂志,2004,84(19):1614-1619. 被引量：22
2Portolos J, Lopez-Gomez JM, Aljama P. Anemia management and treatment response in patients on hemodialysis: the MAR study. J Nephrol, 2006, 19: 352-360.
3Riedel MK, Morqenstern T. Iron replacement in hemodialysis patients with a normal serum ferfitin level. Dtsch Med Wochenschr, 2004, 129 : 1849-1853.
4Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial, 2000,13 : 381-384.
5Charytan C, Levin N, Saloum MA. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial. Am J Kidney Dis, 2001, 37 : 300-307.
6Michael B, Coyne DW, Steven C. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int, 2002, 61:1830-1839.
7Brookhart MA, Schneeweiss S, Avorn J, et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol, 2008, 19 : 1389-1395.
8Riedel MK, Morgenstern T. Iron replacement in hemodialysis patients with a normal serum ferritin level. Dtsch Med Wochenschr, 2004,129 : 1849-1853.
9Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003 ): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant, 2005, 20 Suppl 3 : iii3- iii 24.
10Lenga I, Lok C, Marticorena R, et al. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol, 2007, 2:688-693.